Treatment preferences among individuals with primary hyperoxaluria type 1 (PH1): a real-world study
This study shows that patients with PH1 value treatments that are convenient and fit their lifestyle.
Authors
- Frank Modersitzki (ORCID: https://orcid.org/0000-0002-5461-8637)
- Sandra Salem (ORCID: https://orcid.org/0009-0005-6732-0492)
- Jing Voon Chen (ORCID: https://orcid.org/0000-0003-3632-6806)
- Matthew Sussman
- David S. Goldfarb (ORCID: https://orcid.org/0000-0002-9215-1273)
- Rebekah Zincavage
- Brad Padilla
Institutions
- NYU Langone Health (US)
- Novo Nordisk (United States) (US)
- New York University (US)
Publication Details
- Journal
- Orphanet Journal of Rare Diseases
- Published
- 2025-05-14
- DOI
- https://doi.org/10.1186/s13023-025-03738-9
- Citations
- 1
- Primary Topic
- Kidney Stones and Urolithiasis Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- Novo Nordisk